- Home
- KG vs NRXS Comparison
KG vs NRXS Comparison
Compare KG & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KG | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Bermuda | United States |
| Employees | 44 | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | KG | NRXS |
|---|---|---|
| Price | $10.76 | $7.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 4.8K | ★ 158.4K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | $1.38 | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $8.07 | $2.20 |
| 52 Week High | $35.37 | $9.33 |
Technical Indicators
Market Signals| Indicator | KG | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 46.48 |
| Support Level | $9.39 | $6.80 |
| Resistance Level | $12.29 | $8.03 |
| Average True Range (ATR) | 0.69 | 0.56 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 81.44 | 19.80 |
Price Performance
Historical ComparisonAbout KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).